5BRINKS H J,WEERWIND P W,BOGDAN S,et al.Does heparin pretreatment affect the haemostatic system during and after cardiopulmonary bypass ?[J].Perfusion,2001,16:3-12.
6LEMMER J H Jr,DESPOTIS G J.Antithrombin Ⅲconcentrate to treat heparin resistance in patients undergoing cardiac surgery[J].J Thorac Cardiovasc Surg,2002,123:213-217.
7LEVY J H,MONTES F,SZLAM F,et al.The in vitro effects of antithrombin Ⅲ on the activated coagulation time in patients on heparin therapy[J].Anesth Analg,2000,90:1076-1079.
8PLEYM H,VIDEM V,WAHBA A,et al.Heparin resistance and increased platelet activation in coronary surgery patients treated with enoxaparin preoperatively[J].Eur J Cardiothorac Surg,2006,29:933-940.
9CHAN T,HWANG N C,LIM C H.A statistical analysis of factors predisposing patients to heparin resistance[J].Perfusion,2006,21:99-103.
10LINDEN M D,SCHNEIDER M,BAKER S,et al.Decreased concentration of antithrombin after preoperative therapeutic heparin does not cause heparin resistance during cardiopulmonary bypass[J].J Cardiothorac Vasc Anesth,2004,18:131-135.
3Wong G C, Giugliano R P ,Antman E M. Use of low-molecular-weight heparins in the management of acute coronary artery syndromes and percutaneous coronary in the intervention. JAMA, 2003 ,289:331-342.
4Cohen M. The role of low-molecular-weight heparin in the management of acute coronary syndromes. J Am Coll Cardiol, 2003,41(4 Suppl S):55s-61s.
5Klein W, Buchwald A, Hillis S E, et al. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease:Fragmin in unstable coronary artery diseases study (FRIC).Circulation, 1997, 96:61-68.
6The FRAX.I.S Study Group. Comparison of two treatment durations (6 days and 14 days)of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction:FRAX.I.S (FRAxiparine in Ischemic Syndrome).Eur Heart J, 1999,20:1553-1562.
7Kaul S, Shah P K. Low molecular weight heparin in acute coronary syndrome: evidence for superior or equivalent efficacy compared with unfractionated heparin. J Am Coll Cardiol, 2000 ,35:1699-1712.
8Goodman S G, Cohen M, Bigonzi F, et al. Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: one-year results of the ESSENCE Study. Efficacy and safety of subcutaneous EnoΧaparin in non-Q wave coronary events.J Am Coll Cardiol, 2000 ,36:693-698.
9Antman E M, McCabe C H, Gurfinkel E P, et al. EnoXaparin preventsdezth and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction(TIMI)11B trial. Circulation, 1999,100:1593-1601.
10Antman E M, Cohen M, Radley D, et al.Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction:TIMI11B-ESSENCE meta-analysis. Circulation, 1999,100:1602-1608.
2Kelly J, HUnt B J, Lewis RR, et al. Anticoagulation or inferior vena cava filter placement for patients with primary intraeerebral hemorrhage developing venous thromboembolism? Stroke, 2003, 34 : 2999-3005.
3Davydov L, Yermolnik M, Cuni LJ. Warfarin and amoxicillin/ clavulanate drug interaction. Ann Pharmacother, 2003, 37: 367 -370.
4Hoffmann TK, Parker DL, Buch HA, et al. Suspected suppression of the INR by thiazolidinediones: interaction between warfarin and TZDs. Ann Pharmacother, 2006, 40: 994-996.
5Chan TY. Drug interactions as a cause of overanticoagulation and bleedings in Chinese patients receiving warfarin. Int J Clin Pharmacol Ther, 1998, 36: 403-405.
6Zhan C, Correa-de-Araujo R, Bierman AS, et al. Suboptimal prescribing in elderly outpatients: potentially harmful drag-drug and drug-disease combinations. J Am Geriatr Soc, 2005, 53: 262 -267.
7Isenberg JS, TU Q, Rainey W. Mammary gangrene associated with warfarin ingestion. Ann Plast Surg, 1996, 37: 553-555.
